Total Funding
64
72
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
38873
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
- Chandler Robinson: Co-Founder and Chief Executive Officer
- Christopher M. Starr: Cofounder & Executive ChairmanPast Role: Raptor Pharmaceuticals, CEO & Co-founder
About the Company
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Its lead compound, Hu-ATN-658, is a novel monoclonal antibody for the potential treatment of several deadly cancers. Hu-ATN-658 targets the urokinase plasminogen activator receptor (uPAR). Cancer Research UK will be conducting
Hu-ATN-658’s early development, including a Phase I clinical trial.
In 2014, Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar founded the company in Wilmette, Illinois.
